Skip to main content
GANX
NASDAQ Life Sciences

Gain Therapeutics' Parkinson's Drug GT-02287 Shows Strong Phase 1b Data, Eyes Q3 Phase 2 Start

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.86
Mkt Cap
$77.63M
52W Low
$1.41
52W High
$4.34
52W Position info
32% above low
Off High info
57% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GANX sits 32% above its 52-week low of $1.41.

Summary

Gain Therapeutics reported Q1 2026 financial results and provided a significant corporate update, primarily highlighting positive Phase 1b clinical data for its lead Parkinson's disease candidate, GT-02287. The company presented data demonstrating central target engagement, beneficial effects on downstream pathway abnormalities, and stable MDS-UPDRS scores over 150 days, alongside an 81% reduction in GluSph in participants with elevated baseline levels. For a clinical-stage biotech with a $77 million market cap, these promising Phase 1b results and the clear timeline for FDA IND clearance in Q2 2026 and Phase 2 initiation in Q3 2026 are highly material catalysts. The data supports the potential disease-modifying properties of GT-02287, which could be a significant differentiator in Parkinson's treatment. Traders will closely monitor the anticipated FDA IND clearance and the commencement of the Phase 2 study, as well as the full Phase 1b results expected in Q4 2026.

At the time of this announcement, GANX was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.6M. The 52-week trading range was $1.41 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.14 info
Change: +$0.0567 (+5%) info
Market Cap: $46.752M info
GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.14 info
Change: -$0.6033 (-35%) info
Market Cap: $46.752M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.14 info
Change: -$0.6158 (-35%) info
Market Cap: $46.752M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.14 info
Change: -$0.8659 (-43%) info
Market Cap: $46.752M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.14 info
Change: -$0.9233 (-45%) info
Market Cap: $46.752M info